Published in:

Open Access 24-06-2024 | Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management

Authors: Tivya Kulasegaran, MBChB, FRACP, Niara Oliveira, MD, FRACP

Published in: Current Treatment Options in Oncology | Issue 7/2024

Opinion statement

The management of metastatic castrate-resistant prostate cancer (mCRPC) has evolved in the past decade due to substantial advances in understanding the genomic landscape and biology underpinning this form of prostate cancer. The implementation of various therapeutic agents has improved overall survival but despite the promising advances in therapeutic options, mCRPC remains incurable. The focus of treatment should be not only to improve survival but also to preserve the patient’s quality of life (QoL) and ameliorate cancer-related symptoms such as pain. The choice and sequence of therapy for mCRPC patients are complex and influenced by various factors, such as side effects, disease burden, treatment history, comorbidities, patient preference and, more recently, the presence of actionable genomic alterations or biomarkers. Docetaxel is the first-line treatment for chemo-naïve patients with good performance status and those who have yet to progress on docetaxel in the castration-sensitive setting. Novel androgen agents (NHAs), such as abiraterone and enzalutamide, are effective treatment options that are utilized as second-line options. These medications can be considered upfront in frail patients or patients who are NHA naïve. Current guidelines recommend genetic testing in mCRPC for mutations in DNA repair deficiency genes to inform treatment decisions, as for example in breast cancer gene mutation testing. Other potential biomarkers being investigated include phosphatase and tensin homologues and homologous recombination repair genes. Despite a growing number of studies incorporating biomarkers in their trial designs, to date, only olaparib in the PROFOUND study and lutetium-177 in the VISION trial have improved survival. This is an unmet need, and future trials should focus on biomarker-guided treatment strategies. The advent of novel noncytotoxic agents has enhanced targeted drug delivery and improved treatment responses with favourable toxicity profiling. Trials should continue to incorporate and report health-related QoL scores and functional assessments into their trial designs.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.CrossRefPubMed

Fitzpatrick JM. Management of localized prostate cancer in senior adults: the crucial role of comorbidity. BJU Int. 2008;101(Suppl 2):16–22. https://doi.org/10.1111/j.1464-410X.2007.07487.x.CrossRefPubMed

Henríquez I, Roach M 3rd, Morgan TM, Bossi A, Gómez JA, Abuchaibe O, et al. Current and emerging therapies for metastatic castration-resistant prostate Cancer (mCRPC). Biomedicines. 2021;9(9) https://doi.org/10.3390/biomedicines9091247.

Anantharaman A, Small EJ. Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment. Expert Rev Anticancer Ther. 2017;17(7):625–33. https://doi.org/10.1080/14737140.2017.1333903.CrossRefPubMed

Devlies W, Eckstein M, Cimadamore A, Devos G, Moris L, Van den Broeck T, et al. Clinical Actionability of the genomic landscape of metastatic castration resistant prostate Cancer. Cells. 2020;9(11) https://doi.org/10.3390/cells9112494.

Barbieri CE, Bangma CH, Bjartell A, Catto JW, Culig Z, Grönberg H, et al. The mutational landscape of prostate cancer. Eur Urol. 2013;64(4):567–76. https://doi.org/10.1016/j.eururo.2013.05.029.CrossRefPubMedPubMedCentral

Boyd LK, Mao X, Lu YJ. The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol. 2012;9(11):652–64. https://doi.org/10.1038/nrurol.2012.185.CrossRefPubMed

Rodríguez Antolín A, Martínez-Piñeiro L, Jiménez Romero ME, García Ramos JB, López Bellido D, Muñoz Del Toro J, et al. Prevalence of fatigue and impact on quality of life in castration-resistant prostate cancer patients: the vital study. BMC Urol. 2019;19(1):92. https://doi.org/10.1186/s12894-019-0527-8.CrossRefPubMedPubMedCentral

Nussbaum N, George DJ, Abernethy AP, Dolan CM, Oestreicher N, Flanders S, et al. Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science. Prostate Cancer Prostatic Dis. 2016;19(2):111–21. https://doi.org/10.1038/pcan.2015.42.CrossRefPubMedPubMedCentral

10.

Posdzich P, Darr C, Hilser T, Wahl M, Herrmann K, Hadaschik B, et al. Metastatic prostate Cancer-a review of current treatment options and promising new approaches. Cancers (Basel). 2023;15(2) https://doi.org/10.3390/cancers15020461.

11.

Sayegh N, Swami U, Agarwal N. Recent advances in the Management of Metastatic Prostate Cancer. JCO Oncol Pract. 2022;18(1):45–55. https://doi.org/10.1200/op.21.00206.CrossRefPubMed

12.••

Sorrentino C, Di Carlo E. Molecular targeted therapies in metastatic prostate Cancer: recent advances and future challenges. Cancers (Basel). 2023;15(11) https://doi.org/10.3390/cancers15112885. This paper is of major importance. This study provides an excellent and comprehensive summary of recent targeted therapies for prostate cancer and future directions. This highlights the urgent need for prostate cancer therapies.

13.

Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242–5. https://doi.org/10.1200/jco.2007.12.4008.CrossRefPubMed

14.

de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–54. https://doi.org/10.1016/s0140-6736(10)61389-x.CrossRefPubMed

15.••

Sumanasuriya S, De Bono J. Treatment of advanced prostate Cancer-a review of current therapies and future promise. Cold Spring Harb Perspect Med. 2018;8(6) https://doi.org/10.1101/cshperspect.a030635. This paper is of major importance. This study outlines current and future prostate cancer treatment is great depth. It also discusses promising biomarkers and its potential use in clinical practice.

16.

Lavaud P, Dumont C, Thibault C, Albiges L, Baciarello G, Colomba E, et al. Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer. Ther Adv Med Oncol. 2020;12:1758835920978134. https://doi.org/10.1177/1758835920978134.CrossRefPubMedPubMedCentral

17.

Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97. https://doi.org/10.1056/NEJMoa1207506.CrossRefPubMed

18.

de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate Cancer. N Engl J Med. 2020;382(22):2091–102. https://doi.org/10.1056/NEJMoa1911440.CrossRefPubMed

19.

Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara PN, Evan YY, George DJ, Chi KN, Saad F, Ståhl O, Olmos D. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2022;23(3):362–7.CrossRefPubMedPubMedCentral

20.

de Bono JS, Marcos EC, Laird DA, Fizazi K, Dorff T, Zhao S, van Oort IM, Gasparro D, Calabrò F, Pignata S, Geczi L, et al. TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage response alterations (DDRm)–exploration of tumors genetics associated with prolonged benefit. Ann Oncol. 2022;33:S1167.CrossRef

21.

Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol. 2017;71(2):151–4.CrossRefPubMed

22.

Mostaghel EA. Abiraterone in the treatment of metastatic castration-resistant prostate cancer. Cancer Manag Res. 2014:39–51.

23.

Rehman Y, Rosenberg JE. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. Drug Des Devel Ther. 2012;6:13–8. https://doi.org/10.2147/dddt.S15850.CrossRefPubMedPubMedCentral

24.

de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005. https://doi.org/10.1056/NEJMoa1014618.CrossRefPubMedPubMedCentral

25.

Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152–60. https://doi.org/10.1016/s1470-2045(14)71205-7.CrossRefPubMed

26.

Kwan EM, Wyatt AW, Chi KN. Towards clinical implementation of circulating tumors DNA in metastatic prostate cancer: opportunities for integration and pitfalls to interpretation. Front Oncol. 2022;12:1054497. https://doi.org/10.3389/fonc.2022.1054497.CrossRefPubMedPubMedCentral

27.

Hatano K, Nonomura N. Genomic profiling of prostate Cancer: an updated review. World J Mens Health. 2022;40(3):368–79. https://doi.org/10.5534/wjmh.210072.CrossRefPubMed

28.

Nakazawa M, Paller C, Kyprianou N. Mechanisms of therapeutic resistance in prostate Cancer. Curr Oncol Rep. 2017;19(2):13. https://doi.org/10.1007/s11912-017-0568-7.CrossRefPubMedPubMedCentral

29.

Hernando Polo S, Moreno Muñoz D, Rosero Rodríguez AC, Silva Ruiz J, Rosero Rodríguez DI, Couñago F. Changing the history of prostate Cancer with new targeted therapies. Biomedicines. 2021;9(4) https://doi.org/10.3390/biomedicines9040392.

30.

Cannan WJ, Pederson DS. Mechanisms and consequences of double-Strand DNA break formation in chromatin. J Cell Physiol. 2016;231(1):3–14. https://doi.org/10.1002/jcp.25048.CrossRefPubMedPubMedCentral

31.

Rose M, Burgess JT, O'Byrne K, Richard DJ, Bolderson E. PARP inhibitors: clinical relevance, mechanisms of action and Tumours resistance. Front Cell Dev Biol. 2020;8:564601. https://doi.org/10.3389/fcell.2020.564601.CrossRefPubMedPubMedCentral

32.

Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Bekelman JE, Cheng H, et al. NCCN guidelines insights: prostate Cancer, version 1.2021. J Natl Compr Cancer Netw. 2021;19(2):134–43. https://doi.org/10.6004/jnccn.2021.0008.CrossRef

33.

Gillessen S, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, et al. Management of Patients with advanced prostate Cancer: report from the advanced prostate Cancer consensus conference 2021. Eur Urol. 2022;82(1):115–41. https://doi.org/10.1016/j.eururo.2022.04.002.CrossRefPubMed

34.

Mateo J, de Bono JS, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for the treatment of patients with metastatic castration-resistant prostate Cancer and alterations in BRCA1 and/or BRCA2 in the PROfound trial. J Clin Oncol. 2024;42(5):571–83. https://doi.org/10.1200/jco.23.00339.CrossRefPubMed

35.

Asim M, Tarish F, Zecchini HI, Sanjiv K, Gelali E, Massie CE, et al. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nat Commun. 2017;8(1):374. https://doi.org/10.1038/s41467-017-00393-y.CrossRefPubMedPubMedCentral

36.

Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, et al. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal. 2017;10(480) https://doi.org/10.1126/scisignal.aam7479.

37.

Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(10):1094–108. https://doi.org/10.1016/s1470-2045(23)00382-0.CrossRefPubMed

38.

Chi KN, Sandhu S, Smith MR, Attard G, Saad M, Olmos D, et al. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann Oncol. 2023;34(9):772–82. https://doi.org/10.1016/j.annonc.2023.06.009.CrossRefPubMed

39.

Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023;402(10398):291–303. https://doi.org/10.1016/s0140-6736(23)01055-3.CrossRefPubMed

40.

Gasmi A, Roubaud G, Dariane C, Barret E, Beauval JB, Brureau L, et al. Overview of the development and use of Akt inhibitors in prostate Cancer. J Clin Med. 2021;11(1) https://doi.org/10.3390/jcm11010160.

41.

Lotan TL, Heumann A, Rico SD, Hicks J, Lecksell K, Koop C, et al. PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort. Oncotarget. 2017;8(39):65566–76. https://doi.org/10.18632/oncotarget.19217.CrossRefPubMedPubMedCentral

42.

Jamaspishvili T, Berman DM, Ross AE, Scher HI, De Marzo AM, Squire JA, et al. Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol. 2018;15(4):222–34. https://doi.org/10.1038/nrurol.2018.9.CrossRefPubMedPubMedCentral

43.

Crabb SJ, Griffiths G, Marwood E, Dunkley D, Downs N, Martin K, et al. Pan-AKT inhibitor Capivasertib with docetaxel and prednisolone in metastatic castration-resistant prostate Cancer: a randomized, placebo-controlled phase II trial (ProCAID). J Clin Oncol. 2021;39(3):190–201. https://doi.org/10.1200/jco.20.01576.CrossRefPubMed

44.

Crabb SJ, Ye D-W, Uemura H, Morris T, Gresty C, Logan J, et al. CAPItello-280: a phase III study of capivasertib and docetaxel versus placebo and docetaxel in metastatic castration-resistant prostate cancer. American Society of Clinical Oncology; 2023.

45.

Sweeney C, Bracarda S, Sternberg CN, Chi KN, Olmos D, Sandhu S, et al. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2021;398(10295):131–42.CrossRefPubMed

46.

Shorning BY, Dass MS, Smalley MJ, Pearson HB. The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling. Int J Mol Sci. 2020;21(12):4507.CrossRefPubMedPubMedCentral

47.

Graff JN, Liang LW, Kim J, Stenzl A. KEYNOTE-641: a phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer. Future Oncol. 2021;17(23):3017–26.CrossRefPubMed

48.

Gratzke C, Kwiatkowski M, De Giorgi U, Martins da Trindade K, De Santis M, Armstrong AJ, et al. KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer. Future Oncol. 2022;18(37):4079–87.CrossRef

49.

Antonarakis ES, Park SH, Goh JC, Shin SJ, Lee JL, Mehra N, et al. Pembrolizumab plus Olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate Cancer: the randomized, open-label, phase III KEYLYNK-010 trial. J Clin Oncol. 2023;41(22):3839–50. https://doi.org/10.1200/jco.23.00233.CrossRefPubMedPubMedCentral

50.

Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate Cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol. 2020;38(5):395–405. https://doi.org/10.1200/jco.19.01638.CrossRefPubMed

51.

Handa S, Hans B, Goel S, Bashorun HO, Dovey Z, Tewari A. Immunotherapy in prostate cancer: current state and future perspectives. Ther Adv Urol. 2020;12:1756287220951404. https://doi.org/10.1177/1756287220951404.CrossRefPubMedPubMedCentral

52.

Hofman MS, Emmett L, Violet JY, Zhang A, Lawrence NJ, Stockler M, et al. TheraP: a randomized phase 2 trial of 177Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (clinical trial protocol ANZUP 1603). BJU Int. 2019;124:5–13.CrossRefPubMed

53.•

Morris MJ, De Bono JS, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION). Am Soc Clin Oncol. 2021; This paper is important. This study demonstrated that in this heavily pretreated mCRPC population with a significant cancer burden, lutetium treatment did not result in severe toxicity and improved quality of life. The results were reported using validated patient-reported outcomes

54.

Fizazi K, Herrmann K, Krause BJ, Rahbar K, Chi KN, Morris MJ, et al. Health-related quality of life and pain outcomes with [177Lu] Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24(6):597–610.CrossRefPubMedPubMedCentral

55.

Sartor AO, Morris MJ, Messman R, Krause BJ. VISION: an international, prospective, open-label, multicenter, randomized phase III study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). American Society of Clinical Oncology; 2020.

56.•

Sartor O, Gauna DC, Herrmann K, de Bono J, Shore N, Chi K, et al. LBA13 phase III trial of [177Lu] Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore). Ann Oncol. 2023;34:S1324–S5. This paper is of importance. It was a well-designed study that examined the use of Lutetium in the taxane naïve patient subgroup. Not only did it publish the clinical outcomes, but it also published the health related QoL results. This demonstrated that patient's QoL did not deteriorate from treatment.CrossRef

Title: Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Authors: Tivya Kulasegaran, MBChB, FRACP
Niara Oliveira, MD, FRACP
Publication date: 24-06-2024
Publisher: Springer US
Keywords: Prostate Cancer
Prostate Cancer
Cytostatic Therapy
Antiandrogens
Targeted Therapy
Cancer Immunotherapy
Enzalutamide
Androgens
Published in: Current Treatment Options in Oncology / Issue 7/2024
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI: https://doi.org/10.1007/s11864-024-01215-2

An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant Gliomas

Glioma

Underlying Mechanisms of Thrombosis Associated with Cancer and Anticancer Therapies

Thrombosis

Targeted Therapies in Low-Grade Serous Ovarian Cancers

Open Access
Ovarian Cancer

Novel therapies for anaplastic thyroid cancer

Thyroid Cancer
Review

External Beam Radiotherapy in the Management of Uveal Melanoma

Open Access
Choroidal Melanoma

Neoadjuvant Immunotherapy in Non-melanoma Skin Cancers of the Head and Neck

Cutaneous Squamous Cell Carcinoma

Women’s health knowledge hub

Menopause
Clinical Collection

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Genetic Testing
On-demand Webinar

In this interactive webinar, experts Dr. Subbiah, Dr. Drilon, and Dr. Williams discuss best pathological practices within NSCLC and thyroid cancer, as well as how genomic testing can improve outcomes in clinical practice, using patient case studies as illustrations.

This content is intended only for US-based healthcare providers.

Supported by:

Illumina, Inc., and Eli Lilly and Company

Dr. Vivek Subbiah

Dr. Alexander Drilon

Dr. Michelle Williams

Developed by: Springer Healthcare

Watch now

Elevate your expertise in aplastic anemia (Link opens in a new window)

Aplastic Anemia
Independent Medical Education

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases.

Supported by:

Pfizer

Developed by: Springer Healthcare IME

Learn more

Navigating neuroimaging in Alzheimer disease care

Springer Medicine

Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management

Opinion statement

Other articles of this Issue 7/2024

An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant Gliomas

Underlying Mechanisms of Thrombosis Associated with Cancer and Anticancer Therapies

Targeted Therapies in Low-Grade Serous Ovarian Cancers

Novel therapies for anaplastic thyroid cancer

External Beam Radiotherapy in the Management of Uveal Melanoma

Neoadjuvant Immunotherapy in Non-melanoma Skin Cancers of the Head and Neck

Women’s health knowledge hub

Incorporating comprehensive genomic profiling into the standard-of-care for NSCLC and thyroid cancer

Elevate your expertise in aplastic anemia (Link opens in a new window)

Navigating neuroimaging in Alzheimer disease care

Springer Medicine

Opinion statement

Please log in to get access to this content